Boston Heart Diagnostics Launches LipoMap

One of the Most Comprehensive Assessments of Lipid Metabolism Available

Boston Heart Diagnostics is pleased to announce the availability of LipoMap™. This panel of 33 lipid, lipoprotein, and apolipoprotein tests is performed via high-resolution 600 MHz nuclear magnetic resonance (NMR) and is one of the most comprehensive assessments of lipid metabolism commercially available.

Under-treated lipid abnormalities contribute to ongoing artery damage, a very common cause of premature cardiovascular disease (CVD) and sudden death. LipoMap™ supports healthcare providers to reduce risk and improve outcomes for patients by identifying hidden anomalies. Despite continued efforts, CVD remains the leading cause of death within the United States and throughout the world. This innovative tool from Boston Heart supports clinicians’ ongoing mission to reduce this disease.

LipoMap™ uncovers a wide variety of treatable and reversible lipid abnormalities that cause CVD, both in patients treated with statin medications and in those who have normal levels of low-density lipoprotein (LDL) cholesterol. Unmasking these characteristics allows for greater personalization of treatment, such as improved medication regimens and targeted lifestyle intervention. Follow-up LipoMap™ testing empowers doctors and patients to measure improvements resulting from enhanced treatments.

LipoMap™ is available from Boston Heart and can be ordered exclusively by healthcare professionals. Just 1 mL of blood is required as the test sample, and results are reported within a week via a secure portal. The report provides overall treatment recommendations, interpretations, and explanations for each of the 33 lipid, lipoprotein, and apolipoprotein test results. These include basic lipids, direct LDL-C, small-dense LDL-C, apoA-I, ApoA-II, ApoB, and particle concentrations for LDL, IDL, VLDL, HDL and six subspecies of LDL particles. LipoMap™ also provides the concentration of ApoB-100 and triglycerides contained in the LDL, IDL, and VLDL particles, and relevant ratios, including free versus esterified cholesterol in HDL and LDL which are increased in certain treatable conditions.

Healthcare providers can access LipoMap™ by contacting Boston Heart Diagnostics at 877.425.1252 or by emailing customercare@bostonheartdx.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version